Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 2 pages · Chinese
Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix
Earlier from Sichuan Biokin Pharmaceutical
- Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Iza-Bren (an EGFR×HER3 Bispecific Antibody-Drug Conjugate) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma
- Announcement on Signing Strategic Cooperation Agreement with Bank of China Limited, Sichuan Branch
- Announcement on Resolutions of the 3rd Meeting of the 5th Board of Directors
- Announcement on Replacing Self-raised Funds Invested in Advance in Investment Projects Financed by Raised Funds and Paid for Issuance Fee with Raised Funds
- Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC
Later from Sichuan Biokin Pharmaceutical
- Announcement on Voluntary Disclosure of Milestone Payment Received by Wholly-owned Subsidiary Systimmune and Bristol-Myers Squibb for the Global Strategic Cooperation Agreement of iza-bren
- Announcement on Proposed Application for Registration and Issuance of Debt Financing Instruments
- Announcement on Resolutions of the 5th Meeting of the 5th Board of Directors
- Announcement on Voluntary Disclosure of Inclusion of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma into the Priority Review Program
- Biokin to Present at J.P. Morgan's 44th Annual Healthcare Conference
Follow Sichuan Biokin Pharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Biokin Pharmaceutical